Oppenheimer lowered the firm’s price target on Evolent Health (EVH) to $6 from $12 and keeps an Outperform rating on the shares following the company’s Q4 earnings release and newly issued guidance. The firm is lowering FY2026/2027 EPS estimates and issuing an initial FY2028 EPS estimate. Overall, Oppenheimer believes the more conservative posture toward reserves and the upside to margins from the significant new business, sets the company up for outsized growth in the coming years.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health: Conservative 2026 Guidance Masks Attractive Valuation and Upside to EBITDA Targets
- Evolent Health Charts Growth Amid 2026 Margin Squeeze
- Evolent Health price target lowered to $5 from $10 at UBS
- Evolent Health price target lowered to $4 from $6 at Citi
- Evolent Health price target lowered to $6 from $10 at Truist